Floatz logo

LEUPROLIDE

Brain Cancer

St. Jude Children's Research Hospitalprotein_peptidePhase 1Dormant
CC
44/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
81/ 100

Competitive context

29 Active assets in the Brain Cancer cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Essen Biotech
Phase 2BB
DIANHYDROGALACTITOL
Kintara Therapeutics, Inc.
Phase 2BB
Eloxatin
Northwell Health
Phase 2B
Carboplatin
John L. Villano, MD, PhD
Phase 3B
Capecitabine
Northwell Health
Phase 2B

View all 50 →

Same molecule, other indications

LEUPROLIDE is also rated in:

prostate carcinomaDormant
BBB
Indicative ·
74 / 100
View asset →
metastatic prostate carcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
prostate neoplasmDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →